Brokerages Set Twist Bioscience Co. (NASDAQ:TWST) Price Target at $51.22

Twist Bioscience Co. (NASDAQ:TWST) has been assigned an average rating of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $51.78.

TWST has been the subject of several analyst reports. Scotiabank increased their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 19th. Robert W. Baird increased their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research report on Tuesday, November 19th. Evercore ISI lifted their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Barclays decreased their price objective on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Finally, Leerink Partners boosted their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th.

Twist Bioscience Price Performance

Shares of NASDAQ TWST opened at $46.40 on Tuesday. Twist Bioscience has a 1-year low of $23.07 and a 1-year high of $60.90. The business has a fifty day moving average price of $43.78 and a 200 day moving average price of $46.15. The stock has a market capitalization of $2.75 billion, a P/E ratio of -12.89 and a beta of 1.78.

Insider Buying and Selling

In other Twist Bioscience news, SVP Paula Green sold 1,057 shares of the company’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $41.56, for a total value of $43,928.92. Following the sale, the senior vice president now directly owns 121,013 shares of the company’s stock, valued at approximately $5,029,300.28. This represents a 0.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Dennis Cho sold 1,507 shares of Twist Bioscience stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $48.00, for a total value of $72,336.00. Following the transaction, the insider now owns 91,163 shares of the company’s stock, valued at $4,375,824. The trade was a 1.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 98,118 shares of company stock worth $4,391,151 in the last 90 days. Insiders own 3.92% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Hedge funds have recently bought and sold shares of the stock. State Street Corp raised its holdings in Twist Bioscience by 19.9% in the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares during the period. Geode Capital Management LLC increased its position in shares of Twist Bioscience by 1.9% in the third quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock valued at $61,807,000 after buying an additional 26,145 shares in the last quarter. Thrivent Financial for Lutherans acquired a new position in shares of Twist Bioscience during the 3rd quarter worth approximately $43,992,000. Wellington Management Group LLP lifted its position in shares of Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after buying an additional 521,272 shares in the last quarter. Finally, Fred Alger Management LLC grew its stake in Twist Bioscience by 17.1% in the 3rd quarter. Fred Alger Management LLC now owns 767,149 shares of the company’s stock valued at $34,660,000 after acquiring an additional 112,272 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.